(Total Views: 790)
Posted On: 11/30/2020 8:04:37 PM
Post# of 72440
"Cure for the common cold"
When I scanned the PR this AM I thought the same as your quote, but when you read the PR more carefully what they are referring to is the small percentage {15-20%} of common colds caused by older, less dangerous forms of Coronavirus.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171723/
https://www.webmd.com/cold-and-flu/cold-guide...old_causes
It is possible Brilacidin will be active against other enveloped viruses which cause the common cold symptoms; such as, rhinoviruses, adenovirus, influenza, parainfluenza,RSV and others. I look for IPIX to pursue this goal of studying Brilacidin as a broad spectrum antiviral.
https://www.amboss.com/us/knowledge/General_virology
Imagine going to the doctor with cold symptoms and have your doctor tell you he was going to write a prescription for a Brilacidin inhaler because it was active against the viruses which have the most serious complications.
The RBL seems interested in studying Brilacidin against additional viruses:
"Staff scientists at the RBL will evaluate Brilacidin’s potential inhibitory efficacy against SARS-CoV-2 in lung epithelial cell lines, as well as its potential inhibitory effect in viral replication of the alphavirus (with Venezuelan Equine Encephalitis Virus [VEEV] as a prototype) in different cell lines. "
http://www.ipharminc.com/press-release/2020/3...s-covid-19
IPIX and RBL collaborated for a grant in June 2020
" the Company and researchers at a U.S. Regional Biocontainment Laboratory (RBL) are collaborating on a federal grant application to be submitted this week.
The proposed research aims to evaluate Brilacidin as a potential pan-coronavirus therapeutic, for treating SARS-CoV-2, SARS-CoV-1 and MERS-CoV,"
http://www.ipharminc.com/press-release/2020/6...herapeutic
GLTA, Farrell
When I scanned the PR this AM I thought the same as your quote, but when you read the PR more carefully what they are referring to is the small percentage {15-20%} of common colds caused by older, less dangerous forms of Coronavirus.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171723/
https://www.webmd.com/cold-and-flu/cold-guide...old_causes
It is possible Brilacidin will be active against other enveloped viruses which cause the common cold symptoms; such as, rhinoviruses, adenovirus, influenza, parainfluenza,RSV and others. I look for IPIX to pursue this goal of studying Brilacidin as a broad spectrum antiviral.
https://www.amboss.com/us/knowledge/General_virology
Imagine going to the doctor with cold symptoms and have your doctor tell you he was going to write a prescription for a Brilacidin inhaler because it was active against the viruses which have the most serious complications.
The RBL seems interested in studying Brilacidin against additional viruses:
"Staff scientists at the RBL will evaluate Brilacidin’s potential inhibitory efficacy against SARS-CoV-2 in lung epithelial cell lines, as well as its potential inhibitory effect in viral replication of the alphavirus (with Venezuelan Equine Encephalitis Virus [VEEV] as a prototype) in different cell lines. "
http://www.ipharminc.com/press-release/2020/3...s-covid-19
IPIX and RBL collaborated for a grant in June 2020
" the Company and researchers at a U.S. Regional Biocontainment Laboratory (RBL) are collaborating on a federal grant application to be submitted this week.
The proposed research aims to evaluate Brilacidin as a potential pan-coronavirus therapeutic, for treating SARS-CoV-2, SARS-CoV-1 and MERS-CoV,"
http://www.ipharminc.com/press-release/2020/6...herapeutic
GLTA, Farrell
(15)
(0)Scroll down for more posts ▼
